Soleno Therapeutics, Inc.
-
Ticker
SLNO
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 1-10 Employees
- Based in Redwood City, California
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
REPORT RATINGS
4.8 / 5.0 (111)
Soleno Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 111 reviews.
Soleno Therapeutics, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports